drugset / Trial / NCT00987948

Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

NCT00987948

Phase 2 Completed 15 enrolled University of Hawaii Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

High levels of HIV infection within blood monocyte/macrophages (a type of white cells in the bloodstream) increases risk of dementia in HIV-infected individuals. Maraviroc (Selzentry) is a HIV medication that works by blocking the entry of HIV in cells including monocytes/macrophages that use a receptor called CCR5. The study hypothesis is that the addition of Maraviroc to a HIV antiretroviral regimen in HIV-infected individuals with high levels of HIV-infected monocyte/macrophages will lead to a decrease in the levels of infected monocyte/macrophages and to decrease in brain inflammation as studied by magnetic resonance spectroscopy (MRS, a form of MRI study).

Timeline

Start
2010-01
Primary completion
2012-11
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Maraviroc Other / unclassified